ClinicalTrials.gg
RecruitingNCT07702162Updated Jul 14, 2026

A Clinical Study of PA5 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of PA5 in Advanced Solid Tumors and Cancer, sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2025, registered Jul 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if PA5 is safe and works to treat advanced solid tumors in adults. It will also learn about the tolerability and PK/PD profile of PA5. The main questions it aims to answer are:

  • Is intravenous infusion of PA5 monotherapy safe and tolerable for patients with advanced/metastatic solid tumors?
  • What is the maximum tolerated dose (MTD) and recommended dose for Phase II clinical trials (RP2D) of PA5 monotherapy?

In the escalation phase, participants will receive PA5 via intravenous infusion on Day 1 of Cycle 1 (28-day cycle). If no dose-limiting toxicity (DLT) occurs, treatment continues from Cycle 2 onward with adjusted frequency (every 2-4 weeks).

In the expansion phase, participants will receive PA5 with the frequency determined based on the results of the escalation phase.

Read the detailed description

This is an open-label, single-arm Phase I clinical study evaluating dose escalation and expansion of PA5 monotherapy in patients with advanced solid tumors. The study consists of two parts: a dose escalation phase to determine the safety, tolerability, and PK/PD profile of PA5, and a dose expansion phase to further assess its safety, pharmacodynamics, and efficacy. The study aims to define the effective dose range for PA5 monotherapy and provide a basis for future Phase II studies (monotherapy or combination therapy). A total of 31-49 participants will be enrolled (13-25 in escalation, 18-24 in expansion).

02

Conditions studied

  • Advanced Solid Tumors
  • Cancer

Browse trials for

Keywords

  • Advanced solid tumors
  • Pegylated Arginine Deiminase Dimer
  • PA5
  • Arginine Deiminase
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 49 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Chongqing Peg-Bio Biopharm Co., Ltd. is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years, male or female.
  • Patients with or cytologically confirmed advanced/ solid tumors that are unresectable, stage III or IV, have failed standard therapy, are intolerant to standard therapy, have no standard therapy available, or unable to benefit from standard therapy.
  • At least one evaluable lesion (dose escalation phase) or at least one (dose expansion phase) according to v1.1 criteria.
  • (ECOG) performance status of 0 or 1.
  • Expected of at least 12 weeks.
  • must be well-controlled and without epileptic symptoms.
  • Participants must have adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  • Participants who have received chemotherapy, targeted therapy, anti-tumor Chinese herbal medicine, or palliative care within 2 weeks or 5 half-lives (whichever is longer) prior to the initiation of study treatment; or major surgery, radiotherapy, immunotherapy, or participation in another clinical trial within 4 weeks or 5 half-lives (whichever is longer); or within 4 weeks or inactivated vaccination within 2 weeks prior to initiation of study treatment.
  • Presence of pleural effusion or ascites requiring clinical intervention (except for participants not requiring drainage or with stable effusion for ≥2 weeks after drainage); presence of pericardial effusion (except for minimal, stable effusion for ≥2 weeks).
  • Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 2 per v5.0 (excluding toxicities judged by the investigator to pose no safety risk, such as alopecia).
  • Participants taking drugs known to prolong the or with risk factors for QTc interval prolongation.
  • active bacterial, fungal, or viral infection.
  • Other besides the indication under study, either currently or in the past, except for: cured cervical carcinoma in situ (stage IB or lower), non-invasive basal cell or squamous cell skin cancer, malignant melanoma with complete remission (CR) >10 years, or other malignancies with CR >5 years.
  • Pregnant or breastfeeding women.
  • History of allergy to polyethylene glycol compounds.
  • Prior treatment with ADI-PEG20 or other drugs of the same class.
  • The investigator believes the subject is unsuitable for participating in this clinical study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    PA5

    In the escalation phase, participants will receive PA5 via intravenous infusion on Day 1 of Cycle 1 (28-day cycle). If no dose-limiting toxicity (DLT) occurs, treatment continues from Cycle 2 onward with adjusted frequency (every 2-4 weeks) at dose escalation levels of 0.1, 0.2, 0.4, 0.8, or 1.2 mg/kg. In expansion phase, participants will receive PA5 via intravenous infusion with the frequency determined based on the results of the escalation phase.

    Biological: PA5

Interventions

  • BiologicalPA5

    Administration is performed via intravenous infusion. A single dose is administered in the first cycle; the second cycle is tentatively scheduled for once every two weeks, with 4 weeks defined as one treatment cycle. Dosing continues until the occurrence of disease progression, intolerable toxicity, death, a decision made by the investigator, or voluntary withdrawal of the participant.

    Also known as: Pegylated Arginine Deiminase Dimer

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicity (DLT)

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. The maximum tolerated dose (MTD)

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  3. Adverse Events (AEs)

    including the incidence of overall and categorized AEs, severity (graded according to NCI CTCAE v5.0), seriousness, relationship to PA5 treatment, duration, and outcome.

    Time frame: From Day 1 of Cycle 1 to Day 28 of Cycle 7 (each cycle is 28 days) or to the end of the treatment (whichever occurs earlier)

  4. Recommended phase 2 dose (RP2D) of PA5

    Determine RP2D based on the efficacy and safety of PA5 during the dose escalation and expansion phases

    Time frame: On Day 28 of Cycle 7 (each cycle is 28 days) or at the end of the treatment (whichever occurs earlier)

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 14 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 14 months is below that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 14, 2026
StartActual
Nov 14, 2025
Primary completionEst.
Feb 2, 2027
CompletionEst.
Jun 4, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07702162
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Nov 14, 2025
Primary completion
Feb 2, 2027 (estimated)
Completion
Jun 4, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Jing Sun
Contact
sunj@pegbiocq.com
+86-13983367811

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion